Intriguingly, the synergistic cytotoxic activity of everolimus/AZA combination was more relevant in MZ‐CRC‐1 (harboring RET‐M918T mutation) than in TT (harboring RET‐C634W mutation) cells (Table 1). This evidence concerns the gene RET and colorectal carcinoma.